The company emphasised that it is ready to meet the growing demand for drug-device combinations and biologics, with ...

Revlimid is a medicine used to treat certain cancers and serious conditions affecting blood cells and bone marrow.

Ladies and gentlemen, good day and welcome to the Quarter Three FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only ...

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

Extending losses for the second session, Dr Reddy’s shares dropped 6.65% to hit a low of ₹1,203.60 on the BSE as investors weighed weak Q3 results.

Dr Reddy’s shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay Stock Exchange (BSE).

Shares of Dr Reddy's Laboratories Ltd tumbled more than 6.65 per cent to Rs 1,203.60 on Friday, with its total market capitalisation slipping below Rs 1 lakh crore mark.

Dr Reddy's Laboratories share price plunged 6.66 per cent at Rs 1,203.50 per share on the NSE in Friday's intraday deals after analysts remained cautious on the company's Q3 performance ...

The pharmaceutical company's owners have agreed to pay US7.4 billion ($11.7 billion) and relinquish ownership of the company.

LCMC Health officials announced the activation of their code grey plan at hospitals across the Greater New Orleans region.

MALONE — Union officials confirmed that on Wednesday multiple correction officers and staff were recently treated at a ...

To attain goals, you need confidence. It takes self-assurance to pursue what matters most to you. But too much confidence has ...